HD003

To screen the hair colouring properties of hair colorants/ herbal hair colouring formulations.

The dried aqueous herbal extracts of Gudhal leaves (Hibiscus rosa-sinensis), Jatamansi rhizome (Nardostachys jatamansi), Kuth roots (Saussurea lappa), Kattha (Acacia catechu), Amla dried fruit (Embelica officinalis), were prepared. Coffee powder (Coffea arabica) and Henna powder (Lowsonia inermis) were taken in the form of powder (# 40). Fourteen herbal hair colorants were prepared from these dried aqueous herbal extracts and powders. Activities of hair colorants were observed on sheep wool fibers. On the basis of the above observation six hair colorants were selected. These six formulations were taken for trials on human beings.

The formulation coded HD-3 gave maximum colouring effect on sheep wool fibers as well as on human beings and percentage of acceptance among the volunteers were in the following order: HD- 3 > HD- 4 > HD-1 > HD-13 > HD-14 > HD-11.

The remarkable results were obtained from five herbal hair colorants, viz., HD-1, HD- 3, HD- 4, HD-13 and HD-14 on sheep wool fibers and human beings. Formulation HD-3, having gudhal, jatamansi, kuth, kattha, amla, coffee and henna, was the maximum accepted formulation and suggested that these herbs in combination acts synergistically in hair colouring action. It also concluded that jatamansi, present in different hair colorants, was responsible to provide maximum blackening on hair.

The benzopyranopyrrole S33084 displayed pronounced affinity (pK(i) = 9.6) for cloned human hD(3)-receptors, and >100-fold lower affinity for hD(2) and all other receptors (>30) examined. S33084 concentration dependently, potently, and competitively (pA(2) = 9.7) antagonized dopamine (DA)-induced [(35)S]guanosine-5'- O-(3-thio)triphosphate (GTPgammaS) binding at hD(3)-receptors. It also concentration dependently abolished stimulation by DA of hD(3)-receptor-coupled mitogen-activated protein kinase. Administered alone, S33084 did not modify dialysate levels of DA in the frontal cortex, nucleus accumbens, or striatum of freely moving rats, nor the firing rate of ventrotegmental dopaminergic cell bodies. Furthermore, it had minimal effect on DA turnover in mesocortical, mesolimbic, and nigrostriatal projection regions. However, S33084 dose dependently blocked the suppressive influence of the preferential D(3)-agonist PD128,907 on frontocortical release of DA. Furthermore, it likewise antagonized the inhibitory influence of PD128,907 on the electrical activity of ventrotegmental dopaminergic neurons. Although less potent than S33084, GR218,231 likewise behaved as a selective hD(3)- versus hD(2)-receptor antagonist and its neurochemical and electrophysiological profiles were similar. In contrast, L741,626 was a preferential antagonist at hD(2) versus hD(3) sites. In vivo, on administration alone, L741,626 increased frontocortical, mesolimbic, and (more potently) striatal DA release, enhanced the firing rate of dopaminergic perikarya, and accelerated cerebral DA synthesis. It also blocked the actions of PD128,907. In conclusion, S33084 is a novel, potent, selective, and competitive antagonist at hD(3)-receptors. Although GR218,231 behaves similarly, L741,626 is a preferential D(2)-receptor antagonist. DA D(2)- but not D(3)-(auto) receptors tonically inhibit ascending dopaminergic pathways, although the latter may contribute to phasic suppression of DA release in frontal cortex.